HubMOL · Hub Molecules of Metabolism and Signalling – Key regulators of Life
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2025-01-01 → 2028-12-31
- Финансиране от ЕС
- 4 181 040 €
- Участници
- 21
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите.
Накратко на български
Централните молекули на метаболизма, като ATP и витаминните кофактори, се изследват като регулатори на клетъчните функции. Разбирането на тяхната роля помага при справянето с метаболитни нарушения, рак и невродегенеративни заболявания, както и при разработването на индивидуални режими за прием на витамини.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Metabolic disorders are a major burden on the European population and health care systems. Moreover, metabolic perturbations contribute substantially to other pathologies such as neurodegenerative disorders and cancer. The causes of metabolic dysregulation are manifold and lead to pathological shifts, often in response to imbalanced nutrition. Likewise, changes in metabolism affect signalling mechanisms and gene regulation, aggravating the pathology. The mechanisms of this interdependence between metabolism and signalling are still not well understood. HubMOL will fill this knowledge gap and open new horizons by exploring the functional duality of a set of small molecules that are involved in all cellular functions - the Hub Molecules Of Life (HubMOLs) including ATP, SAM (S-adenosylmethionine) and the vitamin-derived cofactors, NAD, FAD, and CoA. They are key components of both metabolism and signalling networks and are interconnected, for example, through their participation in posttranslational protein modifications (PTMs). The complexity of this emerging area requires interdisciplinary scientists equipped with comprehensive competences covering experimental, computational and systems biology as well as clinical medicine. Therefore, the main HubMOL goal is to provide world-class training in these areas to 16 DCs enabling them to establish fundamentally new insights into cofactor biology and lay the ground for patient-tailored vitamin supplementation concepts. The strategic exposure of the 16 young researchers to leading European academic institutions, companies and clinical environments combined with systematic training in entrepreneurship and transferable skills will strongly improve their employability for positions in both private and public sectors. HubMOL will impact patients and society by developing therapies for metabolic and regulatory imbalances based on hub molecule biology.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET · TromsoКоординаторНорвегия
- ACADEMISCH ZIEKENHUIS GRONINGEN · GroningenНидерландия
- Beilstein-Institut zur Förderung der Chemischen Wissenschaften · Frankfurt Am MainГермания
- CONSIGLIO NAZIONALE DELLE RICERCHE · RomaИталия
- EISBACH BIO GMBH · PLANEGG- MARTINSRIEDГермания
- FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS · BadalonaИспания
- KOBENHAVNS UNIVERSITET · KOBENHAVNДания
- Kingman FilmproduksjonНорвегия
- LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN · PlaneggГермания
- MIMETAS BV · LeidenНидерландия
- MS-OMICS APS · VEDAEKДания
- RIJKSUNIVERSITEIT GRONINGEN · GroningenНидерландия
- SIMULA RESEARCH LABORATORY AS · OsloНорвегия
- SOCIETE DES PRODUITS NESTLE SA · VEVEYШвейцария
- UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI · CasertaИталия
- UNIVERSITAET INNSBRUCK · InnsbruckАвстрия
- UNIVERSITAET LEIPZIG · LeipzigГермания
- UNIVERSITAETSKLINIKUM ESSEN · EssenГермания
- UNIVERSITAT AUTONOMA DE BARCELONA · Cerdanyola Del VallesИспания
- UNIVERSITETET I BERGEN · BergenНорвегия
- Waters Ges.m.b.H. · WienАвстрия
Връзки
Данни: CORDIS, © Европейски съюз